LENZ Therapeutics, Inc. (LENZ) Stock Price & Analysis
LENZ Therapeutics, Inc. (LENZ) closed at USD 3.25 on Thursday, October 22, 2026, up 0.93% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 3.22; the Oct 22, 2026 session ranged USD 3.18–3.29 on volume of 435,385 shares. Market capitalization is $102.12M, with a 52-week range of USD 3.12–32.92 (NMS). Source: Nexqual, retrieved October 23, 2026 at 12:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LENZ.md
Key facts (LENZ)
- Last four reported quarters (through Jun 30, 2026): revenue $21.5M, net income -$126M (-586.7% margin), free cash flow -$114M (SEC filings).
- Analysts: Buy (mean 2.29 on a 1–5 scale) (7 analysts), mean target USD 20 (range 5–50).
- Total return with dividends: 1Y -89.6% vs S&P 500 +14.9%; 5Y -92.1% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD -0.95, revenue estimate $4.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LENZ)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0K | $19.1M | $21.5M |
| Gross profit | — | — | — | $0K | $18.7M | — |
| Operating income | -$60.4M | -$106M | -$72.4M | -$58.6M | -$91.1M | -$136M |
| Net income | -$70.8M | -$101M | -$70.0M | -$49.8M | -$82.1M | -$126M |
| EPS (diluted) | -$17.15 | -$12.88 | -$35.71 | -$2.34 | -$2.85 | — |
| Free cash flow | -$58.6M | -$94.6M | -$60.4M | -$59.9M | -$70.0M | -$114M |
| Gross margin | — | — | — | — | 97.8% | — |
| Operating margin | — | — | — | — | -477.5% | -631.7% |
| Net margin | — | — | — | — | -430.3% | -586.7% |
| Cash + short-term investments | $377M | $284M | $184M | $209M | $292M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (LENZ)
P/S 4.8x · P/B 0.5x · FCF yield -112.05% · Earnings yield -123.39%
Analysts (LENZ)
Consensus Buy (mean 2.29 on a 1–5 scale), 7 analysts; mean target USD 20 (low 5, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Target lowered | Buy | $60 → $50 |
| 2026-10-19 | Piper Sandler | Target lowered | Neutral | $7 → $5 |
| 2026-08-12 | Piper Sandler | Target lowered | Neutral | $12 → $7 |
| 2026-07-07 | HC Wainwright & Co. | Reiterated | Buy | $38 |
Total return (dividends reinvested) (LENZ)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -89.6% | -92.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -89.7% | -39.7% |
| Volatility (annualized) | 83.0% | 80.2% |
| Max drawdown | -90.0% (Oct 2025→Oct 2026) | -93.3% (Sep 2025→Oct 2026) |
LENZ revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| License revenue | $3.8M | 68.4% | -25.0% |
| Product sales, net | $1.7M | 31.6% | — |
| Total revenue | $5.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
LENZ suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Ji Xing Pharmaceuticals Hong Kong | “In addition, we have entered into a license and collaboration agreement (the "CORXEL License") with CORXEL Pharmaceuticals (formerly known as Ji Xing Pharmaceuticals Hong Kong Limited) ("CORXEL") to develop and commercialize LNZ100 (commercially known as VIZZ in the U.S.) in Greater China, a license and commercialization agreement with Lotus Pharmaceutical Co. LTD. (the "Lotus License") to commercialize VIZZ in th…” |
| Partner | Lotus Pharmaceutical | “In addition, we have entered into a license and collaboration agreement (the "CORXEL License") with CORXEL Pharmaceuticals (formerly known as Ji Xing Pharmaceuticals Hong Kong Limited) ("CORXEL") to develop and commercialize LNZ100 (commercially known as VIZZ in the U.S.) in Greater China, a license and commercialization agreement with Lotus Pharmaceutical Co. LTD. (the "Lotus License") to commercialize VIZZ in th…” |
| Competitor | AbbVie (ABBV) | “As VIZZ is marketed for the treatment of presbyopia, we may face competition from a variety of companies developing or marketing other pharmaceutical presbyopia therapies, including AbbVie (formerly Allergan), AceVision, Amneal Therapeutics, Bausch & Lomb, Eyenovia, Glaukos, Johnson & Johnson, Orasis, OSRX Pharmaceuticals (an affiliate of Ocular Science), Viatris (through licensing of Opus Genetics' presbyopia pro…” |
| Competitor | Johnson & Johnson (JNJ) | “As VIZZ is marketed for the treatment of presbyopia, we may face competition from a variety of companies developing or marketing other pharmaceutical presbyopia therapies, including AbbVie (formerly Allergan), AceVision, Amneal Therapeutics, Bausch & Lomb, Eyenovia, Glaukos, Johnson & Johnson, Orasis, OSRX Pharmaceuticals (an affiliate of Ocular Science), Viatris (through licensing of Opus Genetics' presbyopia pro…” |
Quoted from the company's 10-K filed Mar 24, 2026.
LENZ customer concentration
In the period ended Dec 31, 2025, 3 direct customers each accounted for at least 10% (18%, 17%, 15%) of revenue, per the company's 10-K filed Mar 24, 2026. The company does not name them.
LENZ analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.95 | $-0.94 | +0.9% | $4.2M | 6 |
| Next quarter (ends Dec 2026) | $-0.88 | $-1.00 | -12.0% | $4.6M | 5 |
| Current fiscal year (ends Dec 2026) | $-4.18 | $-4.56 | -8.5% | $16.0M | 6 |
| Next fiscal year (ends Dec 2027) | $-2.73 | $-3.51 | -22.3% | $37.6M | 6 |
LENZ options: expected move
Options price a move of about ±42.8% (±$1.38) by Jan 15, 2027, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±9.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Jan 15, 2027 | 84 | 124.9% | ±42.8% |
| Mar 19, 2027 | 147 | 421.7% | ±42.1% |
| Apr 16, 2027 | 175 | 305.2% | ±96.6% |
30-day implied volatility 85% vs 57.6% realized over the last 30 trading days. Put/call ratio (volume) 15.8. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 12:51 UTC)
| Price | USD 3.25 |
|---|---|
| Change | ▲ 0.93% (up) |
| Previous Close | USD 3.22 |
| Open | USD 3.25 |
| Day Range | USD 3.18 – 3.29 |
| 52-Week Range | USD 3.12 – 32.92 |
| Volume | 435,385 shares |
| Market Cap | $102.12M |
| Exchange | NMS |
Technical Analysis (LENZ)
Nexqual's technical model rates LENZ "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 12:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.74 (oversold) |
| vs SMA50 | Below (USD 4.25) |
| MACD | -0.3 (negative) |
Analyst Ratings (LENZ)
Wall Street analysts rate LENZ "Buy" based on 7 analysts, with a mean price target of USD 20 (range USD 5–50), per Nexqual as of October 23, 2026 at 12:51 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 20 |
| High Target | USD 50 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 5 / 2 / 0 |
Earnings (LENZ)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD -0.95 |
| Revenue Estimate | $4.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.02 vs est -1.07 ▲ beat |
| 2026-03-31 | USD -1.32 vs est -1.07 ▼ miss |
| 2025-12-31 | USD -1.16 vs est -0.92 ▼ miss |
| 2025-09-30 | USD -0.59 vs est -0.69 ▲ beat |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financials & Fundamentals (LENZ)
| Total Revenue | $21.48M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.70% |
| Gross Margin | +91.74% |
| Operating Margin | -622.89% |
| Profit Margin | +0.00% |
| ROE | -59.21% |
| Debt / Equity | 0 |
| Current Ratio | 13.55 |
| Total Cash | $220.00M |
| Total Debt | $569,000 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$114.42M (-532.8% of revenue) |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financial Health Score (LENZ)
Nexqual rates LENZ Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 12:51 UTC.
| Growth | Solid — Revenue +10% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $220M cash, no debt |
| Cash Flow | Weak — FCF negative: -$114M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -59%, ROA -37.4% |
Ownership (LENZ)
| Insider Ownership | +2.65% |
|---|---|
| Institutional Ownership | +110.08% |
| Shares Outstanding | 31.42M |
| Float | 18.39M |
| Short % of Float | +55.29% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Leadership (LENZ)
LENZ Therapeutics, Inc. is led by Evert B. Schimmelpennink, President, CEO, Secretary & Director, per Nexqual as of October 23, 2026 at 12:51 UTC.
| President, CEO, Secretary & Director | Evert B. Schimmelpennink |
|---|---|
| Co-Founder & Director | James W. McCollum |
| Chief Financial Officer | Daniel R. Chevallard |
| Vice President of Sales | Domenick Porfidia |
| Vice President of Marketing | David Choromanski |
Major Backers & Investors (LENZ)
Notable institutional backers of LENZ Therapeutics, Inc. include RA Capital Management, L.P., Alpha Wave Global, LP, FMR, LLC, according to Nexqual as of October 23, 2026 at 12:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 13.3% |
| Alpha Wave Global, LP | 11.5% |
| FMR, LLC | 11.33% |
| Versant Venture Management, LLC | 8.46% |
| Squarepoint Ops LLC | 5.56% |
| Aberdeen Group plc | 4.93% |
| Millennium Management | 4.8% |
| Fidelity | 4.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.3% |
| Vanguard Group | 3.49% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
From LENZ Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Based on these positive results in our Phase 3 trial, we selected VIZZ as our lead product candidate and submitted a New Drug Application ("NDA") to the FDA in August 2024.
- License and Distribution Agreements." In March 2026, we announced the submission of a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for the review and approval of VIZZ.
- Our sales strategy empowers ECPs to be actively involved in the diagnosis and treatment of presbyopia for the aging population, including a consumer sampling program described in "Consumer Sampling Strategy." Subsequent to FDA approval and commercial launch of VIZZ, we have seen more ECPs begin to prescribe prescription-based eye drops, which will drive more patients requesting prescriptions who otherwise may not have sought appointments with ECPs for other eye conditions.
- A Drug Master File ("DMF") is on file with the FDA for the API.
Partnerships
- We also entered into a distribution agreement with Lunatus Global Medical Supplies (the "Lunatus Distribution Agreement") to sell VIZZ in a nine-country region in the Middle East, including the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq (collectively, the "Middle East").
Legal & Regulatory Risks (Item 1A, quoted)
- We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.
- We may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings.
- Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations and can face serious consequences for violations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 12:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt